Quality control in multicentric clinical trials. An experience of the EORTC gynecological cancer cooperative group

被引:19
|
作者
Favalli, G
Vermorken, JB
Vantongelen, K
Renard, J
Van Oosterom, AT
Pecorelli, S
机构
[1] Univ Antwerp Hosp, Dept Med Oncol, B-2650 Edegem, Belgium
[2] Univ Brescia, Spedali Civili, Dept Gynecol Oncol, Brescia, Italy
[3] Univ Hosp Gasthuisberg, Dept Oncol, B-3000 Louvain, Belgium
[4] Eortc Data Ctr, Brussels, Belgium
关键词
quality control; multicentric trials; chemotherapy;
D O I
10.1016/S0959-8049(00)00090-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Data Quality is a central requirement of scientific research and external monitoring is essential in multicentric clinical trials (MCT). A quality control (QC) study was conducted in the main Institutions participating in EORTC-GCCG Protocol number 55863 - randomised phase III trial of vindesine. cisplatin, bleomycin and mitomycin-C (BEMP) versus cisplatin (P) in disseminated squamous cell carcinoma of the uterine cervix - in order to assess the impact of variations in data quality on the conclusions of the trial. The reliability of the different centres in following the protocol was investigated by a questionnaire covering drug prescription, local facilities and the procedure for preparation and administration of chemotherapy. The 'treatment protocol adherence' was evaluated by recalculation of the ideal protocol dose and its comparison with the actual delivered dosage at each cycle of chemotherapy. 'Data quality control' was assessed by comparison of data on case report forms (CRFs) with the corresponding items in the medical records. Eleven centres participating in the trial were visited by the same team of reviewers. Striking differences were noted in the chemotherapy administration procedures and between the type and quality of hospital files. Overall. there was an acceptable level of data quality and protocol compliance. Data accuracy was 81.8% (range: 65.6-97%) of the 4424 items checked. Incorrect data were found in 7.0% (2.3-14.5%), data were missing on the form in 3.6% of cases (0-12%) and data was on the form but not in the file in 7.6% of cases (0.7-17.5%). Causes of inaccuracy were analysed. Both problems in data management but also in a lack of clarity of the protocol and/or CRFs were to blame. Training and supervision of data managers, precision in writing protocols, standardisation of some aspects of CRFs and the use of a checklist for chemotherapy data and treatment toxicities would have avoided many of these errors. The need for QC in all collaborative groups performing MCT is emphasised. A literature review on QC in MCT dealing with chemotherapy is included. (C) 2000 Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1125 / 1133
页数:9
相关论文
共 50 条
  • [31] Prevalence of quality of life(QoL) outcomes and association with survival in cancer clinical trials.
    Gyawali, Bishal
    Hwang, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Etoposide in malignant pleural mesothelioma: Two phase II trials of the EORTC Lung Cancer Cooperative Group
    Sahmoud, T
    Postmus, PE
    van Pottelsberghe, C
    Mattson, K
    Tammilehto, L
    Splinter, TAW
    Planting, AST
    Sutedja, T
    van Pawel, J
    van Zandwijk, N
    Baas, P
    Roozendaal, KJ
    Schrijver, M
    Kirkpatrick, A
    Van Glabbeke, M
    Ardizzoni, A
    Giaccone, G
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (13) : 2211 - 2215
  • [33] Measuring Quality of Life among Cancer Patients in Clinical Trials. A Bibliometric Study
    Sanchez, Ricardo
    Ballesteros, Monica
    Gomez Auli, Alejandro
    REVISTA COLOMBIANA DE CANCEROLOGIA, 2009, 13 (01): : 29 - 34
  • [34] QUALITY ASSURANCE CONTROL IN THE EORTC COOPERATIVE GROUP OF RADIOTHERAPY .3. INTERCOMPARISON IN AN ANATOMICAL PHANTOM
    JOHANSSON, KA
    HORIOT, JC
    VANDERSCHUEREN, E
    RADIOTHERAPY AND ONCOLOGY, 1987, 9 (04) : 289 - 298
  • [35] THE ECONOMIC BENEFITS OF RHEUMATOLOGY CLINICAL TRIALS. THE CANNOCK EXPERIENCE
    Joshi, Piyush
    Venkatachalam, Srinivasan
    Edwards, Julie
    Sheeran, Thomas
    RHEUMATOLOGY, 2017, 56 : 30 - 30
  • [36] Topotecan in colorectal cancer: A phase II study of the EORTC early clinical trials group
    Creemers, GJ
    Wanders, J
    Gamucci, T
    Vallentin, S
    Dirix, LY
    Schoffski, P
    Hudson, I
    Verweij, J
    ANNALS OF ONCOLOGY, 1995, 6 (08) : 844 - 846
  • [37] CLINICAL COOPERATIVE TRIALS OF THE NATIONAL-CANCER-INSTITUTE-OF-CANADA CLINICAL-TRIALS-GROUP BREAST-CANCER-SITE-GROUP
    PRITCHARD, KI
    CANCER, 1994, 74 (03) : 1150 - 1155
  • [38] PHASE-II TRIAL OF BLEOMYCIN IN PATIENTS WITH ADVANCED OVARIAN-CANCER - AN EORTC GYNECOLOGICAL CANCER COOPERATIVE GROUP-STUDY
    VERMORKEN, JB
    ARMAND, JP
    LACAVE, AJ
    GEORGE, M
    DEOLIVEIRA, CF
    CHEIX, F
    MASKENS, AP
    ROTMENSZ, N
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (06): : 671 - 673
  • [39] PHASE-II TRIAL OF MEDROXYPROGESTERONE ACETATE IN ADVANCED OVARIAN-CANCER - AN EORTC GYNECOLOGICAL CANCER COOPERATIVE GROUP-STUDY
    HAMERLYNCK, JVTH
    MASKENS, AP
    MANGIONI, C
    VANDERBURG, MEL
    WILS, JAMJ
    VERMORKEN, JB
    ROTMENSZ, N
    GYNECOLOGIC ONCOLOGY, 1985, 22 (03) : 313 - 316
  • [40] IMPROVING DOCUMENTATION AND QUALITY OF PEDIATRIC CANCER CARE WITHIN THE PARADIGM OF COOPERATIVE GROUP CLINICAL RESEARCH TRIALS
    Beaty, Orren
    Bottom, Krystal
    Bowers, Anne
    Clarke, Melanie T.
    Grogan, Karen
    PEDIATRIC BLOOD & CANCER, 2013, 60 : S90 - S90